ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology.
Journal
JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
medline:
13
7
2023
pubmed:
8
4
2023
entrez:
7
4
2023
Statut:
ppublish
Résumé
As the voice of cancer care clinicians and the patients they serve, ASCO has taken steps to elevate awareness about biosimilar products and their use in oncology. In 2018, ASCO released its Statement on Biosimilars in Oncology which was subsequently published in the
Substances chimiques
Biosimilar Pharmaceuticals
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM